Physician profile
Michael B Furman
NPI 1184623795
$4,591.81
in general payments reported to CMS, 2019-2025
12 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,392 · 2020: $95.30 · 2021: $453 · 2022: $403 · 2023: $547 · 2024: $505 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $1,814.76 | 2019 | |
| Boston Scientific Corporation | $978.57 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, Patient Trial Kit |
| Vertos Medical, INC. | $463.54 | 2022-2024 | Mild Device Kit |
| Abbott Laboratories | $341.22 | 2019-2022 | |
| Relievant Medsystems, INC. | $333.76 | 2019-2023 | Intracept |
| Si-Bone, INC. | $165.14 | 2019-2021 | |
| Spr Therapeutics, INC | $141.43 | 2023 | Sprint Pns System |
| Medtronic, INC. | $128.15 | 2021 | |
| Nevro Corp. | $83.19 | 2019 | |
| Philips North America LLC | $81.88 | 2019-2020 | |
| Biotronik Nro, INC. | $60.17 | 2024 | Prospera |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Furman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.